Abstract:Objective:To explore the genetic mutation, clinical characteristics, diagnosis and treatment of patients with hereditary coagulation factor FⅪ deficiency.Methods:On August 10 and October 30, 2020, two patients with hereditary FⅪ deficiency who were admitted at Department of Hematology, West China Hospital of Sichuan University were selected as research subjects. Patients 1 and 2 were numbered according to visiting time. Diagnosis was made according to coagulation function test and results of gene sequencing F11 gene.Clinical observation or symptomatic treatment were performed according to clinical bleeding symptom and severity. Novel mutations were confirmed by retrieving Human Gene Mutation database (HGMD), Single Nucleotide Polymorphism Database (dbSNP) and PubMed database. Pathogenicity of the novel missense mutation was predicted by computational software of Mutation Taster, Polyphen-2, and PROVEAN. Follow-up of patients was conducted until February 28, 2021. Clinical manifestations and process of diagnosis and treatment of two patients were analyzed retrospectively. China National Knowledge Infrastructure database, Wanfang Data Knowledge Service Platform, PubMed database were searched for the same and similar case reports as F11 genetic mutation in this study.Retrieval time was from database inception to February 28, 2021. Types of genetic mutations and clinical manifestations related to patients in this study were summarized.This study meeted the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Informed consent of patients was obtained from pateints. Results:① Results of medical history: patient 1, a 24 years old man, was admitted due to " hematoma after soft tissue trauma in left thigh and preoperative examination revealed coagulation dysfunction" and did not complain of significant discomfort.Patient 2, a 32 years old woman, was admitted due to " pre-pregnancy physical examination found prolonged activated partial thromboplastin time (APTT)" and complained of occasional ecchymosis.② Results of related laboratory examination: APTT, prothrombin time (PT) and FⅪ activity (FⅪ∶C) of patient 1 were 97.9 s, 11.9 s and 0.6%, while patient 2 were 95.4 s, 12.5 s, and 1.2%, respectively. ③ Results of DNA sequencing: patient 1 had a compound heterozygous missense mutation of F11 gene at c. 149G>T(p.Cys50Phe) and c. 1204C>T (p.Gln402Ter), while patient 2 had a homozygous deletion of F11 gene at c. 1058delA (p.Asn353ThrfsTer18). ④ F11 gene missense mutation at c. 149G>T(p.Cys50Phe) and deletion c. 1058delA(p.Asn353ThrfsTer18) were two novel mutations and both were pathogenic.⑤Results of treatment and follow-up: two patients received clinical observation. At end of follow-up, general condition of the patients was good. ⑥ Results of literatures review: among 10 patients reported in 6 relevant literatures, there were 1, 3, 6 patients caused by heterozygous nonsense mutation of c. 1204C>T(p.Gln402Ter), nonsense mutation of c. 1202C>T(p.Trp401Ter) adjacent to c. 1204C>T (p.Gln402Ter) and missense mutations near the position of c. 149G>T(p.Cys50Phe), respectively. Conclusions:Two novel mutations of hereditary FⅪ deficiency namely a missense mutation at c. 149G>T(p.Cys50Phe) and a deletion at c. 1058delA(p.Asn353ThrfsTer18) of F11 gene were reported in this study. Both of the two mutations related to decrease of FⅪ∶C.

Mutation Detection and Inhibitor Analysis of 43 Children with Severe Hemophilia A in a Single Center: Three Novel Mutations

Genetic analysis of patients with hereditary coagulation factor Ⅺ deficiency and literatures review

An Intronic Mutation C.6430-3C>g in the F8 Gene Causes Splicing Efficiency and Premature Termination in Hemophilia A

[Mutation screening of the F VIII gene in 10 hemophilia A families].

Genetic Analysis and Reproductive Interventions for Two Rare Families Affected by Severe Haemophilia A

Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study

A Novel Deletion Mutation of the F8 Gene for Hemophilia A

[Molecular Analysis of a Patient with Hemophilia A Caused by FVIII His99Arg Mutation].

Prevalence of the Factor 8 Gene Intron 1 Inversion in Chinese Haemophiliacs and Its Application to Carrier Detection and Prenatal Diagnosis in Haemophilia A Families

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.

Detection by Denaturing Gradient Gel Electrophoresis of an Arg1689Cys Mutation in a Chinese Patient with Mild Hemophilia A.

Molecular pathogenesis of two novel splice site mutations of F8 in hemophilia A

Clinical Retrospective Analysis of 780 Patients with Haemophilia A Single Haemophilia Center

Carrier Detection and Prenatal Diagnosis of Hemophilia A.

[Intron 1 and 22 Inversions in Factor VIII Gene in Patients with Haemophilia A].

A Post Hoc Analysis of Previously Untreated Patients (PUPs) With Severe Hemophilia A Who Developed Inhibitors in PUPs A-LONG

Risk factors associated with inhibitor development in Chinese patients with haemophilia B.

Detection of hemophilia A genetic variants using third-generation long-read sequencing

Peripheral Blood Lymphocyte Subsets in Factor VIII Inhibitor-Positive Patients with Severe Hemophilia A: A Case-Control Study

Compound Heterozygous Hemophilia A in a Female Patient and the Identification of a Novel Missense Mutation, P.met1093ile